e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS

Summary by AI BETAClose X

Tangram Therapeutics, formerly e-therapeutics, announced its corporate relaunch and the unveiling of LLibra OS, a new AI platform. The company is focused on advancing a pipeline of GalOmic RNAi medicines, with lead program TGM-312 for MASH expected to have a CTA submission in Q4 2025. Additionally, TGM-148 for bleeding disorders is progressing through IND-enabling studies, with a regulatory submission planned for 2026. The LLibra OS platform is designed to accelerate the discovery and evaluation of gene targets and siRNA design.

Disclaimer*

UK 100

Latest directors dealings